<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00302</drugbank-id>
  <drugbank-id>APRD01270</drugbank-id>
  <drugbank-id>EXPT00508</drugbank-id>
  <name>Tranexamic acid</name>
  <description>Antifibrinolytic hemostatic used in severe hemorrhage.</description>
  <cas-number>1197-18-8</cas-number>
  <unii>6T84R30KC1</unii>
  <average-mass>157.2102</average-mass>
  <monoisotopic-mass>157.110278729</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Noa Zerangue, Bernd Jandeleit, Yunxiao Li, "Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use." U.S. Patent US20070027210, issued February 01, 2007.</synthesis-reference>
  <indication>For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.</indication>
  <pharmacodynamics>Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).</pharmacodynamics>
  <mechanism-of-action>Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.</mechanism-of-action>
  <toxicity>Oral LD&lt;sub&gt;50&lt;/sub&gt; in mice is &gt;10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.</toxicity>
  <metabolism>Only a small fraction of the drug is metabolized (less than 5%).</metabolism>
  <absorption>Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.</absorption>
  <half-life>Biological half-life in the joint fluid is about 3 hours.</half-life>
  <protein-binding>The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen (does not bind serum albumin).</protein-binding>
  <route-of-elimination>Urinary excretion is the main route of elimination via glomerular filtration.</route-of-elimination>
  <volume-of-distribution>* 9 to 12 L</volume-of-distribution>
  <clearance>* 110 - 116 mL/min</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as amino acids. These are organic compounds that contain at least one carboxyl group and one amino group.</description>
    <direct-parent>Amino acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aliphatic homomonocyclic compound</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="french" coder="inn">Acide tranéxamique</synonym>
    <synonym language="spanish" coder="inn">ácido tranexámico</synonym>
    <synonym language="latin" coder="inn">Acidum tranexamicum</synonym>
    <synonym language="english" coder="inn/usan">Tranexamic acid</synonym>
    <synonym language="german" coder="">Tranexamsaeure</synonym>
    <synonym language="english" coder="">Tranexmic acid</synonym>
    <synonym language="english" coder="">Tranhexamic acid</synonym>
    <synonym language="english" coder="">Trans AMCHA</synonym>
    <synonym language="english" coder="">trans-4-(Aminomethyl)cyclohexanecarboxylic acid</synonym>
    <synonym language="english" coder="">trans-4-aminomethylcyclohexane-1-carboxylic acid</synonym>
    <synonym language="english" coder="">trans-Amcha</synonym>
    <synonym language="english" coder="">trans-Tranexamic acid</synonym>
  </synonyms>
  <products>
    <product>
      <name>Cyklokapron</name>
      <labeller>Pharmacia and Upjohn Company</labeller>
      <ndc-id/>
      <ndc-product-code>0013-0114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-01-04</started-marketing-on>
      <ended-marketing-on>2006-01-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>500 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyklokapron</name>
      <labeller>Pharmacia and Upjohn Company LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0013-1114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA019281</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyklokapron 100 mg/ml</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02064413</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cyklokapron 500 mg</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02064405</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Erfa-tranexamic</name>
      <labeller>Erfa Canada 2012 Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02457431</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gd-tranexamic Acid</name>
      <labeller>Genmed A Division Of Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02409097</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gd-tranexamic Acid</name>
      <labeller>Genmed A Division Of Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02409089</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lysteda</name>
      <labeller>Xanodyne Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>66479-650</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-17</started-marketing-on>
      <ended-marketing-on>2010-05-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>650 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022430</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lysteda</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-2100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-17</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>650 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022430</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lysteda</name>
      <labeller>Ferring Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55566-2110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>650 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022430</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lysteda</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401959</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>650.0 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pure Whitenol Serum</name>
      <labeller>Skin M.D. Korea</labeller>
      <ndc-id/>
      <ndc-product-code>69629-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>0.05 mg/50mL</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Skinmd Laboratories Pure Whitenol Intensive</name>
      <labeller>Reviresco Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>71974-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Skinmd Laboratories Pure Whitenol Serum</name>
      <labeller>Reviresco Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>71974-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>0.05 g/50mL</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>SKINMD LABORATORIES ReviTox blue</name>
      <labeller>Reviresco Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>71974-040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic acid</name>
      <labeller>Nexus Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>14789-500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA091596</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>650 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022430</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>650 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022430</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206594</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-20</started-marketing-on>
      <ended-marketing-on>2016-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>650 1/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202286</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206634</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>X Gen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>39822-1000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA201580</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-12</started-marketing-on>
      <ended-marketing-on>2012-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA091657</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic acid</name>
      <labeller>Gland Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68083-160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA207239</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>650 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202093</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3638</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>650 1/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202286</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Athenex Pharmaceutical Division, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70860-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA207239</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>ACELLA PHARMACEUTICALS</labeller>
      <ndc-id/>
      <ndc-product-code>42192-605</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202436</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-891</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205228</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>AMERICAN REGENT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0517-0960</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA201885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Methapharm, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67850-041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202436</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-563</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA091596</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-197</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA091657</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Caplin Steriles Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65145-106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA212360</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Micro Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code>42571-189</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206713</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Micro Labs Limited</labeller>
      <ndc-id/>
      <ndc-product-code>42571-314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206713</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Apollo Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>61990-0611</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA212676</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>AuroMedics Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55150-188</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205035</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA201580</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Methapharm, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67850-042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA209326</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Heritage Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>23155-524</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 g/10mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203521</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Heritage Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>23155-166</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 g/10mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203521</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>X-GEN Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>39822-1001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA201580</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Virtus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69543-376</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-13</started-marketing-on>
      <ended-marketing-on>2020-08-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202755</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-929</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-18</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>650 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202093</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Akorn, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>17478-217</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202373</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA207239</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Amring Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69918-301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>650 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022430</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1398</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA208840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid In Sodium Chloride</name>
      <labeller>Exela Pharma Sciences, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>51754-0108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA212020</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tranexamic Acid Injection</name>
      <labeller>Omega Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392763</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tranexamic Acid Injection</name>
      <labeller>Methapharm, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02454785</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tranexamic Acid Injection</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466015</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tranexamic Acid Injection</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484846</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tranexamic Acid Injection</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484897</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tranexamic Acid Injection BP</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246365</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tranexamic Acid Injection BP</name>
      <labeller>Sterimax Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02386933</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tranexamic Acid Injection BP</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02455900</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tranexamic Acid Tablets</name>
      <labeller>Sterimax Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401231</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Cyclo-F</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Espercil</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Femstrual</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Rikavarin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Transamin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Transcam</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Traxyl</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Lysteda</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Pure Whitenol Serum</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Lysteda</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Cyklokapron</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Cyklokapron</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>SKINMD LABORATORIES ReviTox blue</name>
      <ingredients>Adenosine + Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid In Sodium Chloride</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Lysteda</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Skinmd Laboratories Pure Whitenol Intensive</name>
      <ingredients>Adenosine + Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Skinmd Laboratories Pure Whitenol Serum</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Cyklokapron 500 mg</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Cyklokapron 100 mg/ml</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Injection BP</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Injection BP</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Injection</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Tablets</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Lysteda</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Injection</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Gd-tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Gd-tranexamic Acid</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Injection BP</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Erfa-tranexamic</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Injection</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Injection</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Tranexamic Acid Injection</name>
      <ingredients>Tranexamic acid</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Gallipot</name>
      <url>http://www.gallipot.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>Pharmacia Inc.</name>
      <url>http://www.pharmaciaupjohn.com</url>
    </packager>
    <packager>
      <name>Professional Compounding Centers America LLC</name>
      <url>http://www.pccarx.com</url>
    </packager>
    <packager>
      <name>Xanodyne Pharmaceuticals Inc.</name>
      <url>http://www.xanodyne.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Pharmacia and upjohn co</manufacturer>
    <manufacturer generic="false" url="">Ferring pharmaceuticals as</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Cyklokapron 500 mg Tablet</description>
      <cost currency="USD">1.3</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Tranexamic acid powder</description>
      <cost currency="USD">1.97</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Cyklokapron 100 mg/ml ampul</description>
      <cost currency="USD">8.8</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids, Carbocyclic</category>
      <mesh-id>D000146</mesh-id>
    </category>
    <category>
      <category>Amino Acids</category>
      <mesh-id>D000596</mesh-id>
    </category>
    <category>
      <category>Antifibrinolytic Agents</category>
      <mesh-id>D000933</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Coagulants</category>
      <mesh-id>D003029</mesh-id>
    </category>
    <category>
      <category>Cyclohexanecarboxylic Acids</category>
      <mesh-id>D003509</mesh-id>
    </category>
    <category>
      <category>Cyclohexanes</category>
      <mesh-id>D003510</mesh-id>
    </category>
    <category>
      <category>Cycloparaffins</category>
      <mesh-id>D003516</mesh-id>
    </category>
    <category>
      <category>Decreased Fibrinolysis</category>
      <mesh-id/>
    </category>
    <category>
      <category>Fibrin Modulating Agents</category>
      <mesh-id>D050299</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>500 mg/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>650 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>650.0 mg</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.05 mg/50mL</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.05 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>100 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1 g/10mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>100 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>650 1/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>650 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B02AA02">
      <level code="B02AA">Amino acids</level>
      <level code="B02A">ANTIFIBRINOLYTICS</level>
      <level code="B02">ANTIHEMORRHAGICS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:28.16</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1b2i</pdb-entry>
    <pdb-entry>1ceb</pdb-entry>
    <pdb-entry>5v3c</pdb-entry>
    <pdb-entry>6nmb</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00302.pdf?1265922742</msds>
  <patents>
    <patent>
      <number>8022106</number>
      <country>United States</country>
      <approved>2011-09-20</approved>
      <expires>2025-03-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8273795</number>
      <country>United States</country>
      <approved>2012-09-25</approved>
      <expires>2025-03-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8487005</number>
      <country>United States</country>
      <approved>2013-07-16</approved>
      <expires>2025-03-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8791160</number>
      <country>United States</country>
      <approved>2014-07-29</approved>
      <expires>2025-03-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8809394</number>
      <country>United States</country>
      <approved>2014-08-19</approved>
      <expires>2025-03-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8957113</number>
      <country>United States</country>
      <approved>2015-02-17</approved>
      <expires>2025-03-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9060939</number>
      <country>United States</country>
      <approved>2015-06-23</approved>
      <expires>2025-03-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7947739</number>
      <country>United States</country>
      <approved>2011-05-24</approved>
      <expires>2025-03-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06804</drugbank-id>
      <name>Nonoxynol-9</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Nonoxynol-9.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14583</drugbank-id>
      <name>Segesterone acetate</name>
      <description>Segesterone acetate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00058</drugbank-id>
      <name>Alpha-1-proteinase inhibitor</name>
      <description>Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>Menadione may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00513</drugbank-id>
      <name>Aminocaproic acid</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Aminocaproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11091</drugbank-id>
      <name>Hydrogen peroxide</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Hydrogen peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13244</drugbank-id>
      <name>Aminomethylbenzoic acid</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Aminomethylbenzoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13729</drugbank-id>
      <name>Camostat</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Camostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Etonogestrel may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>Desogestrel may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Megestrol acetate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>Levonorgestrel may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Progesterone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>Medroxyprogesterone acetate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>Norethisterone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>Ethynodiol diacetate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Mifepristone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>Norgestimate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>Nifedipine may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>Mestranol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Drospirenone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04066</drugbank-id>
      <name>para-Coumaric Acid</name>
      <description>para-Coumaric Acid may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Estrone sulfate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04682</drugbank-id>
      <name>Octylphenoxy polyethoxyethanol</name>
      <description>Octylphenoxy polyethoxyethanol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>Cyproterone acetate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05830</drugbank-id>
      <name>Trestolone</name>
      <description>Trestolone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06266</drugbank-id>
      <name>Lonidamine</name>
      <description>Lonidamine may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06713</drugbank-id>
      <name>Norelgestromin</name>
      <description>Norelgestromin may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>Gestodene may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>Hydroxyprogesterone caproate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08867</drugbank-id>
      <name>Ulipristal</name>
      <description>Ulipristal may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Dienogest may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09371</drugbank-id>
      <name>Norethynodrel</name>
      <description>Norethynodrel may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09389</drugbank-id>
      <name>Norgestrel</name>
      <description>Norgestrel may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>Isosorbide may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11507</drugbank-id>
      <name>Cloprostenol</name>
      <description>Cloprostenol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>Gestrinone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>Nomegestrol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>Triptolide may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>Lynestrenol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13044</drugbank-id>
      <name>Gossypol</name>
      <description>Gossypol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13310</drugbank-id>
      <name>Ormeloxifene</name>
      <description>Ormeloxifene may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>Chlormadinone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>Norgestrienone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>Quingestanol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>Demegestone may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13866</drugbank-id>
      <name>Etynodiol</name>
      <description>Etynodiol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Testosterone enanthate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13981</drugbank-id>
      <name>Nomegestrol acetate</name>
      <description>Nomegestrol acetate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14678</drugbank-id>
      <name>Norethindrone enanthate</name>
      <description>Norethindrone enanthate may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09222</drugbank-id>
      <name>Fibrinogen human</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of Thrombosis can be increased when Tretinoin is combined with Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00025</drugbank-id>
      <name>Antihemophilic factor, human recombinant</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Antihemophilic factor, human recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00036</drugbank-id>
      <name>Coagulation factor VIIa Recombinant Human</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00100</drugbank-id>
      <name>Coagulation Factor IX (Recombinant)</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01164</drugbank-id>
      <name>Calcium chloride</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium Chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01783</drugbank-id>
      <name>Pantothenic acid</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Pantothenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01942</drugbank-id>
      <name>Formic acid</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Formic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02261</drugbank-id>
      <name>Platelet Activating Factor</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Platelet Activating Factor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09109</drugbank-id>
      <name>Turoctocog alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Turoctocog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09310</drugbank-id>
      <name>Catridecacog</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Catridecacog.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Antihemophilic Factor (Recombinant), PEGylated.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium Citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium gluconate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11168</drugbank-id>
      <name>Calcium threonate</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium threonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11311</drugbank-id>
      <name>Prothrombin</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Prothrombin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11330</drugbank-id>
      <name>Factor IX Complex (Human)</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium Phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11606</drugbank-id>
      <name>Susoctocog alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Susoctocog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Eftrenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11668</drugbank-id>
      <name>Rusalatide acetate</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Rusalatide acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12409</drugbank-id>
      <name>Vatreptacog alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Vatreptacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12909</drugbank-id>
      <name>Factor XIII (human)</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Factor XIII (human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13133</drugbank-id>
      <name>Von Willebrand Factor Human</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Von Willebrand Factor Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13148</drugbank-id>
      <name>Coagulation factor X human</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13150</drugbank-id>
      <name>Coagulation factor VII human</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Coagulation factor VII human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13151</drugbank-id>
      <name>Anti-inhibitor coagulant complex</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Anti-inhibitor coagulant complex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13152</drugbank-id>
      <name>Coagulation Factor IX Human</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Coagulation Factor IX Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13192</drugbank-id>
      <name>Antihemophilic factor human</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Antihemophilic factor human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13197</drugbank-id>
      <name>Kallidinogenase</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Kallidinogenase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13201</drugbank-id>
      <name>Trenonacog alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Trenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Albutrepenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Emicizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Nonacog beta pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13999</drugbank-id>
      <name>Moroctocog alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Moroctocog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14473</drugbank-id>
      <name>Beroctocog alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Beroctocog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14562</drugbank-id>
      <name>Andexanet alfa</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Andexanet alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Calcium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Damoctocog alfa pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14738</drugbank-id>
      <name>Turoctocog alfa pegol</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Turoctocog alfa pegol.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-0.94</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.82e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>tranexamic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>157.2102</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>157.110278729</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC[C@H]1CC[C@@H](CC1)C(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C8H15NO2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>GYDJEQRTZSCIOI-LJGSYFOKSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>63.32</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>41.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>17.28</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>4.56</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>10.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1.67E+005 mg/L</value>
      <source>MERCK INDEX (1996)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>&gt;300 °C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.3</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1988</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>48669</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5526</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508089</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01136</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>10482000</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50428067</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164750514</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>AMH</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000199</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tranexamic_acid</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL877</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/cyclapron.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/tranexamic-acid.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000287</smpdb-id>
      <name>Tranexamic Acid Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00302</drugbank-id>
          <name>Tranexamic acid</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000211</id>
      <name>Plasminogen</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4538</ref-id>
            <pubmed-id>10400410</pubmed-id>
            <citation>Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32.</citation>
          </article>
          <article>
            <ref-id>A4539</ref-id>
            <pubmed-id>10625440</pubmed-id>
            <citation>Marti DN, Schaller J, Llinas M: Solution structure and dynamics of the plasminogen kringle 2-AMCHA complex: 3(1)-helix in homologous domains. Biochemistry. 1999 Nov 30;38(48):15741-55.</citation>
          </article>
          <article>
            <ref-id>A4540</ref-id>
            <pubmed-id>10673876</pubmed-id>
            <citation>Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K: Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth. 1999 Oct;83(4):596-601.</citation>
          </article>
          <article>
            <ref-id>A4541</ref-id>
            <pubmed-id>10959704</pubmed-id>
            <citation>Bangert K, Thorsen S: Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis. Thromb Haemost. 2000 Aug;84(2):299-306.</citation>
          </article>
          <article>
            <ref-id>A4542</ref-id>
            <pubmed-id>12115473</pubmed-id>
            <citation>Hanson AJ, Quinn MT: Effect of fibrin sealant composition on human neutrophil chemotaxis. J Biomed Mater Res. 2002 Sep 5;61(3):474-81.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00747" source="Swiss-Prot">
        <name>Plasminogen</name>
        <general-function>Serine-type peptidase activity</general-function>
        <specific-function>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</specific-function>
        <gene-name>PLG</gene-name>
        <locus>6q26</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>7.25</theoretical-pi>
        <molecular-weight>90568.415</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9071</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PLG</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X05199</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>387026</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2394</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P00747</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PLMN_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.7</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016037|Plasminogen
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016038|Plasminogen (PLG)
ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
TCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT
GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC
CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT
GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC
TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
GGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00051</identifier>
            <name>Kringle</name>
          </pfam>
          <pfam>
            <identifier>PF00089</identifier>
            <name>Trypsin</name>
          </pfam>
          <pfam>
            <identifier>PF00024</identifier>
            <name>PAN_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>apolipoprotein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein domain specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type peptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibrinolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell-cell adhesion mediated by cadherin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell-substrate adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fibrinolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fibrinolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tissue remodeling</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="2">
      <id>BE0001134</id>
      <name>Solute carrier family 15 member 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A17869</ref-id>
            <pubmed-id>9888294</pubmed-id>
            <citation>Dieck ST, Heuer H, Ehrchen J, Otto C, Bauer K: The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative beta-Ala-Lys-Nepsilon-AMCA in astrocytes. Glia. 1999 Jan;25(1):10-20.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q16348" source="Swiss-Prot">
        <name>Solute carrier family 15 member 2</name>
        <general-function>Peptide:proton symporter activity</general-function>
        <specific-function>Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.</specific-function>
        <gene-name>SLC15A2</gene-name>
        <locus>3q13.33</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>58-78
88-108
115-135
140-160
184-204
218-238
296-316
344-364
381-401
568-588
612-632
644-664
675-695</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.38</theoretical-pi>
        <molecular-weight>81782.77</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10921</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC15A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S78203</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>999213</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q16348</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S15A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Kidney H(+)/peptide cotransporter</synonym>
          <synonym>Oligopeptide transporter, kidney isoform</synonym>
          <synonym>PEPT2</synonym>
          <synonym>Peptide transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037126|Solute carrier family 15 member 2
MNPFQKNESKETLFSPVSIEEVPPRPPSPPKKPSPTICGSNYPLSIAFIVVNEFCERFSY
YGMKAVLILYFLYFLHWNEDTSTSIYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLV
YVLGHVIKSLGALPILGGQVVHTVLSLIGLSLIALGTGGIKPCVAAFGGDQFEEKHAEER
TRYFSVFYLSINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSK
IYNKPPPEGNIVAQVFKCIWFAISNRFKNRSGDIPKRQHWLDWAAEKYPKQLIMDVKALT
RVLFLYIPLPMFWALLDQQGSRWTLQAIRMNRNLGFFVLQPDQMQVLNPLLVLIFIPLFD
FVIYRLVSKCGINFSSLRKMAVGMILACLAFAVAAAVEIKINEMAPAQPGPQEVFLQVLN
LADDEVKVTVVGNENNSLLIESIKSFQKTPHYSKLHLKTKSQDFHFHLKYHNLSLYTEHS
VQEKNWYSLVIREDGNSISSMMVKDTESRTTNGMTTVRFVNTLHKDVNISLSTDTSLNVG
EDYGVSAYRTVQRGEYPAVHCRTEDKNFSLNLGLLDFGAAYLFVITNNTNQGLQAWKIED
IPANKMSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTIAVGNIIV
LVVAQFSGLVQWAEFILFSCLLLVICLIFSIMGYYYVPVKTEDMRGPADKHIPHIQGNMI
KLETKKTKL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010792|Solute carrier family 15 member 2 (SLC15A2)
ATGAATCCTTTCCAGAAAAATGAGTCCAAGGAAACTCTTTTTTCACCTGTCTCCATTGAA
GAGGTACCACCTCGACCACCTAGCCCTCCAAAGAAGCCATCTCCGACAATCTGTGGCTCC
AACTATCCACTGAGCATTGCCTTCATTGTGGTGAATGAATTCTGCGAGCGCTTTTCCTAT
TATGGAATGAAAGCTGTGCTGATCCTGTATTTCCTGTATTTCCTGCACTGGAATGAAGAT
ACCTCCACATCTATATACCATGCCTTCAGCAGCCTCTGTTATTTTACTCCCATCCTGGGA
GCAGCCATTGCTGACTCGTGGTTGGGAAAATTCAAAGTCCTATCATTGATCGGCCTGAGT
CTAATAGCTTTGGGGACAGGAGGCATCAAACCCTGTGTGGCAGCTTTTGGTGGAGACCAG
TTTGAAGAAAAACATGCAGAGGAACGGACTAGATACTTCTCAGTCTTCTACCTGTCCATC
AATGCAGGGAGCTTGATTTCTACATTTATCACACCCATGCTGAGAGGAGATGTGCAATGT
TTTGGAGAAGACTGCTATGCATTGGCTTTTGGAGTTCCAGGACTGCTCATGGTAATTGCA
CTTGTTGTGTTTGCAATGGGAAGCAAAATATACAATAAACCACCCCCTGAAGGAAACATA
GTGGCTCAAGTTTTCAAATGTATCTGGTTTGCTATTTCCAATCGTTTCAAGAACCGTTCT
GGAGACATTCCAAAGCGACAGCACTGGCTAGACTGGGCGGCTGAGAAATATCCAAAGCAG
CTCATTATGGATGTAAAGGCACTGACCAGGGTACTATTCCTTTATATCCCATTGCCCATG
TTCTGGGCTCTTTTGGATCAGCAGGGTTCACGATGGACTTTGCAAGCCATCAGGATGAAT
AGGAATTTGGGGTTTTTTGTGCTTCAGCCGGACCAGATGCAGGTTCTAAATCCCCTTCTG
GTTCTTATCTTCATCCCGTTGTTTGACTTTGTCATTTATCGTCTGGTCTCCAAGTGTGGA
ATTAACTTCTCATCACTTAGGAAAATGGCTGTTGGTATGATCCTAGCATGCCTGGCATTT
GCAGTTGCGGCAGCTGTAGAGATAAAAATAAATGAAATGGCCCCAGCCCAGCCAGGTCCC
CAGGAGGTTTTCCTACAAGTCTTGAATCTGGCAGATGATGAGGTGAAGGTGACAGTGGTG
GGAAATGAAAACAATTCTCTGTTGATAGAGTCCATCAAATCCTTTCAGAAAACACCACAC
TATTCCAAACTGCACCTGAAAACAAAAAGCCAGGATTTTCACTTCCACCTGAAATATCAC
AATTTGTCTCTCTACACTGAGCATTCTGTGCAGGAGAAGAACTGGTACAGTCTTGTCATT
CGTGAAGATGGGAACAGTATCTCCAGCATGATGGTAAAGGATACAGAAAGCAGAACAACC
AATGGGATGACAACCGTGAGGTTTGTTAACACTTTGCATAAAGATGTCAACATCTCCCTG
AGTACAGATACCTCTCTCAATGTTGGTGAAGACTATGGTGTGTCTGCTTATAGAACTGTG
CAAAGAGGAGAATACCCTGCAGTGCACTGTAGAACAGAAGATAAGAACTTTTCTCTGAAT
TTGGGTCTTCTAGACTTTGGTGCAGCATATCTGTTTGTTATTACTAATAACACCAATCAG
GGTCTTCAGGCCTGGAAGATTGAAGACATTCCAGCCAACAAAATGTCCATTGCGTGGCAG
CTACCACAATATGCCCTGGTTACAGCTGGGGAGGTCATGTTCTCTGTCACAGGTCTTGAG
TTTTCTTATTCTCAGGCTCCCTCTAGCATGAAATCTGTGCTCCAGGCAGCTTGGCTATTG
ACAATTGCAGTTGGGAATATCATCGTGCTTGTTGTGGCACAGTTCAGTGGCCTGGTACAG
TGGGCCGAATTCATTTTGTTTTCCTGCCTCCTGCTGGTGATCTGCCTGATCTTCTCCATC
ATGGGCTACTACTATGTTCCTGTAAAGACAGAGGATATGCGGGGTCCAGCAGATAAGCAC
ATTCCTCACATCCAGGGGAACATGATCAAACTAGAGACCAAGAAGACAAAACTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00854</identifier>
            <name>PTR2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antibiotic transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dipeptide transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high-affinity oligopeptide transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>